Description
GLP-1 is NuLumin’s designation for semaglutide, a synthetic peptide research compound that acts at the glucagon-like peptide-1 receptor. In laboratory research it is used as a reference incretin-pathway agonist.
Preclinical literature describes investigations into glucose control, insulin output, appetite-linked behavior, and GLP-1 receptor signaling, carried out using cell-based assays and animal studies. Its single defined target makes it a clean incretin comparator.
Intended use: In vitro and preclinical in vivo laboratory research only. Not approved for human or veterinary use.
Reviews
There are no reviews yet.